| Nasdaq: ONTY
Oncothyreon, Inc. is clinical-stage bio-pharmaceutical company. Primarily, it is focused on the development of therapeutic products for the treatment of cancer. The company's cancer vaccines are designed to stimulate the immune system to attack cancer cells, while small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. It operates through a single segment: research and development of therapeutic products for the treatment of cancer. Oncothyreon was founded on September 7, 2007 and is headquartered in Seattle, WA.